Avidity Biosciences Gains FDA Orphan Drug Designation for Patients With DMD
October 9th 2023Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).
Read More
Lung Effects of Particulate Matter Exposure in WTC First Responders Still Redound Decades Later
October 9th 2023New research explores the risk factors for lung disease in firefighters who were exposed to particulate matter when responding to the attacks on the World Trade Center (WTC) on September 11, 2001, as well as interventions that may mediate inflammatory responses.
Read More
Experts Debate Terminology and Treatment of Asthma-COPD Overlap
October 9th 2023As evidenced by a debate at the CHEST Annual Meeting 2023, the pulmonology community disagrees on whether the overlap of asthma and chronic obstructive pulmonary disease (COPD) is a distinct entity and how best to treat it.
Read More
Mobile Mammography Unit Increases Breast Cancer Screening Among Latina Patients
October 7th 2023Pinky, a mobile mammography unit from Stony Brook University Hospital Cancer Center on Long Island, increased screening for breast cancer from 9% to 69% among the predominantly Latina population that it serves.
Read More
Many Cases of Adult-Onset T1D Are Diagnosed After Age 30, Study Finds
October 7th 2023In the overall population of more than 1.3 million US adults, 37% of patients reported being diagnosed with T1D after 30 years, with men and racial or ethnic minorities diagnosed later compared with women and non-Hispanic White adults.
Read More
Mike Koroscik Discusses Population Health Reimbursement Models and Increased Lung Cancer Screening
October 7th 2023Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute, discusses the successes and challenges of a population health reimbursement model and gives advice for other health organizations considering a similar partnership within their practices.
Watch
Dr Afreen Idris Shariff on the Value of e-Consults for Endocrine Toxicities of ICIs
October 7th 2023Afreen Idris Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, discusses how e-consults are addressing specific endocrine immune-related adverse events from immune checkpoint inhibitors (ICIs), reducing time to appointment, and lowering the need for hospitalization.
Watch
Dempsey Center Research Demonstrates Importance of Supporting Oncology Care Providers
October 6th 2023The interrelated concepts of burnout, secondary traumatic stress, moral distress, compassion fatigue, and compassion satisfaction have been identified as having a profound impact on the quality of life of health care providers.
Read More